AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

When the body treats a therapeutic antibody as foreign, it produces anti-drug antibodies that can blunt the drug’s effect, change how it moves through the body and raise safety concerns. The FDA’s ...
Clinical Pain Advisor

Eptinezumab Reduces Headache Days in Difficult-to-Treat Migraine

Eptinezumab treatment reduces monthly migraine days and acute medication use in patients with difficult-to-treat episodic or chronic migraine.

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients ...
FT Markets

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies ...
pharmaphorum

UEGW delegates hear of strides forward in IBD treatment

While relatively uncommon, UC that starts in childhood tends to be more extensive and severe than when it emerges in ...
Baptist Health South Florida

Breast Cancer During Pregnancy: Protecting Two Futures at Once

Breast cancer during pregnancy can often be treated safely. Lynn Cancer Institute and Lynn Women’s Institute experts explain ...
The Daily Reflector

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained ...

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies ...

Holland Park dog parks in Palm Coast close after reported parvo case

Palm Coast officials said the temporary closure would last approximately one month as staff works to disinfect the sites.
MarketScreener

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd The U.S. is experiencing a record-breaking number of measles cases in 2026, ...
jen.jiji

Protests in Milan, "concern" for Saturday: security plan with paratroopers and drones kicks in

Milan is preparing for a high-tension Saturday, with an extraordinary plan to prevent new unrest after last weekend's devastations. 500 paratroopers from the Folgore brigade are arriving from Siena, ...
jen.jiji

US Elections, simulations and lawyers: the Democrats' defense against Trump's 'threats'

The stated goal is to create a defense network aimed at protecting the integrity of the popular vote from any anomaly or abuse of power by the federal government. Led by key figures from both Chambers ...

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, registrational trial ...